Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics


Milestone Pharmaceuticals Inc. (MIST): $4.94

0.08 (+1.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MIST Stock Price Chart Interactive Chart >

Price chart for MIST

MIST Price/Volume Stats

Current price $4.94 52-week high $9.85
Prev. close $4.86 52-week low $3.98
Day low $4.70 Volume 57,900
Day high $4.96 Avg. volume 266,959
50-day MA $6.16 Dividend yield N/A
200-day MA $6.43 Market Cap 169.37M

Milestone Pharmaceuticals Inc. (MIST) Company Bio


Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.


MIST Latest News Stream


Event/Time News Detail
Loading, please wait...

MIST Latest Social Stream


Loading social stream, please wait...

View Full MIST Social Stream

Latest MIST News From Around the Web

Below are the latest news stories about MILESTONE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIST as an investment opportunity.

Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET. The event will focus on the commercial opportunity for etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycar

Yahoo | November 29, 2022

Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 1:30 p.m. ET in New York, NY.

Yahoo | November 22, 2022

Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 74% over the last three years

Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So...

Yahoo | November 12, 2022

Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2022, and provided a clinical and corporate update.

Yahoo | November 10, 2022

Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the presentation of new data from the Phase 3 RAPID clinical trial of etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting. The presentation, titled "Self-administered Etripamil for Termination of Spontaneous Paroxysmal

Yahoo | November 7, 2022

Read More 'MIST' Stories Here

MIST Price Returns

1-mo -3.89%
3-mo -43.02%
6-mo -11.31%
1-year -15.41%
3-year -70.42%
5-year N/A
YTD -24.58%
2021 -2.24%
2020 -58.15%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5911 seconds.